Joint Formulary & PAD

Montelukast - Asthma

You are here : Home > Formulary Search > Montelukast - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Chewable tablets
  • Sachets (granules)
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :

Documentation

Webpage
NICE NG80 - Asthma-diagnosis-monitoring-and-chronic-asthma-management

PAD Profile

ChemicalSubstance :
Montelukast
Indication :
Asthma
Group Name :
Keywords :
Leukotriene receptor antagonists, LTRAs
Brand Names Include :
Singulair
Important Information :

https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Asthma
Supporting Documents :
1

Committee Recommendations (1)

06 Mar 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Montelukast may be an appropriate first-line addition to ICS (particularly if atopy or allergic component).

Prescribe generically (the brand Singulair was assigned a BLACK traffic light status by the PCN in May 2017)

The guidelines for Asthma can be found below

Other Indications

Below are listed other indications that Montelukast is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Asthma.